Evotec AG has achieved a milestone in its biomarker alliance with Roche. Roche will use a response prediction marker, identified using Evotec’s Proteome Profiling platform, in an extended Phase I oncology trial.   This is the first milestone achieved under the collaboration and license agreement signed in 2011. Under the initial three-year term, Evotec and Roche conduct biomarker discovery and validation programs for patient stratification in targeted cancer therapy. Evotec is eligible for...